roflumilast

(redirected from Daliresp)
Also found in: Medical.
Translations

roflumilast

n roflumilast m
References in periodicals archive ?
This decrease was partially offset by increased revenues of drugs including Pulmicort, Duaklir, and Daliresp.
Daliresp (roflumilast; AstraZeneca): Does Daliresp earn more doctor recommendations for being effective or easy to administer?
The agreement, announced in December 2015, includes the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease.
AstraZeneca, which has marketed roflumilast in the United States under the name Daliresp since the first quarter of 2015, said that it would pay $575 million to Takeda.
Upon completion of the transaction, AstraZeneca will own the development and commercial rights to Tudorza Pressair (aclidinium bromide inhalation powder), a twice-daily long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD), and Daliresp (roflumilast), a once-daily oral PDE4 inhibitor currently on the market for COPD.
AstraZeneca owns the development and commercial rights in the US and Canada to Tudorza Pressair (aclidinium bromide inhalation powder), a twice-daily long-acting muscarinic antagonist for chronic obstructive pulmonary disease, and to Daliresp (roflumilast), the only once-daily oral PDE4 inhibitor currently on the market for COPD, in the US.
Additionally, AstraZeneca will own the development and commercial rights in the US and Canada Daliresp (roflumilast), the only once-daily oral PDE4 inhibitor currently on the market for COPD.
In the US, it is sold as Daliresp by Forest Laboratories Inc (NYSE:FRX).
It will be marketed as Daliresp and is expected to be commercially available later this year.
The deal will include the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD).
Upon completion of the transaction, AstraZeneca will own the development and commercial rights in the US and Canada to Tudorza Pressair (aclidinium bromide inhalation powder), a twice-daily long-acting muscarinic antagonist for chronic obstructive pulmonary disease, and Daliresp (roflumilast), the only once-daily oral PDE4 inhibitor currently on the market for COPD.